Kardiolytics’ VCAST technology receives new U.S. patent for autonomous segmentation using artificial intelligence for vascular disease diagnosis
Kardiolytics’ VCAST technology receives new U.S. patent for autonomous segmentation using artificial intelligence for vascular disease diagnosis.
Kardiolytics Inc., a subsidiary of Medicalgorithmics S.A., a company listed on the Warsaw Stock Exchange, has announced that it has been granted a new U.S. patent, Patent No. 11626211, for its VCAST technology used to diagnose vascular diseases. The patent concerns an autonomous method for modelling blood vessels and blood flow using a CT angiography scan.
The method involves generating a three-dimensional personalized model of the blood vessels and a three-dimensional reference model of healthy blood vessels that lack lesions. The personalized model is then subjected to a numerical simulation of blood flow under the same physical and boundary conditions as the reference model. The simulation involves determining the conditions of blood flow at the inlet of the blood vessels model and calculating the energy of the blood flow for the inlet and all outlets of the model. The blood flow energy measured for the personalized model and the reference model are compared to determine flow energy change indexes. This method can be used to assess the impact of lesions or other abnormalities on blood flow and could potentially be used to diagnose or monitor vascular diseases.
VCAST has several advantages over the invasive procedure used to obtain FFR, including being non-invasive, safer because has a lower radiation dose, and is a time & cost-effective solution for the functional evaluation of stenosed vessels. The VCAST technology offers a comprehensive evaluation of blood flow through the coronary arteries under stress test conditions, providing more diagnostic value than traditional methods. This breakthrough technology has an immense market potential, as it could be used as an alternative to the invasive catheterization procedure currently used to obtain FFR.
It is estimated that the global CT-FFR market will reach USD 1,3 billion by 2026, growing at a CAGR of 15.5% during the next decade. Factors driving the market include the increasing incidence of coronary artery disease, an aging patient population and advancements in CT technology.
This is already a second patent obtained by Kardiolytics in the U.S. this year. In January, the company was granted a patent (US 11521322 B2) for machine learning based segmentation of contrast filled coronary artery vessels on medical images. Automatic detection and segmentation of contrast filled coronary arteries in the images facilitate the diagnosis, treatment, and monitoring of coronary artery diseases.
Securing patents for innovations and technologies will enable Kardiolytics to promote and commercialize inventions. Furthermore, it will help protect Kardiolytics’ unique intellectual property to enable further development of the solution and improve Coronary Artery Disease (CAD) diagnostics. CAD is the most common type of heart disease in the US. About 20.1 million adults aged 20 and older have CAD (CDC data). Kardiolytics’ VCAST technology has immense potential to address unmet needs and revolutionize the prevention and treatment of this disease.